SCHEMBL1385083

SCHEMBL1385083

Cn1cc2c(-c3cccc(O)c3)c(-c3ccncc3)c(-c3ccc(F)cc3)nc2n1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.46
CSNK1D P48730 4/20 0.46
CSNK1E P49674 3/20 0.46
MAPK13 O15264 1/20 0.46
MAPK12 P53778 1/20 0.46
MAPK11 Q15759 1/20 0.46
BRAF P15056 2/20 0.43
CSNK1A1 P48729 2/20 0.43
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
ADORA3 P0DMS8 2/20 0.40
ADORA2A P29274 2/20 0.40
ADORA1 P30542 2/20 0.40
EGFR P00533 1/20 0.40
RAF1 P04049 1/20 0.40
ADORA2B P29275 1/20 0.40
GSK3B P49841 1/20 0.40
NR3C1 P04150 1/20 0.38
PGR P06401 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1384930 0.89 MAPK14 (0.51) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1386962 0.88 MAPK14 (0.57) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1386958 0.85 MAPK14 (0.42) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1384721 0.84 MAPK14 (0.48) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1385623 0.82 PDE10A (0.44) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL2930232 0.81 ADORA3 (0.48) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1384519 0.79 MAPK14 (0.47) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1386698 0.79 MAPK14 (0.54) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1385415 0.79 MAPK14 (0.45) MAPK14CSNK1DCSNK1EMAPK13MAPK12
SCHEMBL1386614 0.79 PDE10A (0.49) MAPK14CSNK1DCSNK1EMAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
JP-4814783-B2 2011-11-16 JP claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach y Compagnia S.A. (ES) 2006-01-04 EP claimed
WO-2004076450-A1 PYRAZOLOPYRIDINE DERIVATES J. Uriach Y Compañia S.A. (ES) 2004-09-10 WO claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885CSNK1D 75/4885CSNK1E 235/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885CSNK1D 60/4885CSNK1E 165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.